LitCovid-sentences  

PMC:7534795 / 35711-39434 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T248 0-111 Sentence denotes Table 5 Overview of proposed pharmacological approaches to attenuate COVID-19 associated cardiovascular injury.
T249 112-218 Sentence denotes Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference
T250 219-370 Sentence denotes • Colchicine for the improvement of cardiac biomarkers, inflammation, and clinical outcomes • Prospective, open-label randomized controlled trial (RCT)
T251 371-407 Sentence denotes • N = 55 colchicine + standard care
T252 408-431 Sentence denotes • N = 50 standard care
T253 432-793 Sentence denotes • Primary endpoints included maximum cardiac troponin level, time for C-reactive protein (CRP) to reach 3× upper limit normal, time to deterioration by at least 2 points on clinical status scale • Colchicine 1.5 mg loading dose, 0.5 mg after 60 min, and then 0.5 mg twice daily + standard care for up to 3 weeks • No difference in cardiac troponin or CRP levels
T254 794-895 Sentence denotes • Clinical deterioration less common with colchicine treatment odd ratio (OR) 0.11 (95% CI 0.01–0.96)
T255 896-1206 Sentence denotes • Abdominal pain and diarrhea significantly more common with colchicine treatment • Colchicine may not have a significant effect on cardiac or inflammatory biomarkers, however it may be useful in stabilizing patients with severe COVID-19 infection and preventing clinical deterioration (Deftereos et al., 2020)
T256 1207-1301 Sentence denotes • Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study
T257 1302-1350 Sentence denotes • Primary endpoint of 28-day all-cause mortality
T258 1351-1401 Sentence denotes • Secondary endpoint included acute cardiac injury
T259 1402-1424 Sentence denotes • N = 1219 statin use
T260 1425-1474 Sentence denotes • N = 12, 762 no statin • In-hospital statin use
T261 1475-1496 Sentence denotes • Atorvastatin 83.2%,
T262 1497-1517 Sentence denotes • Rosuvastatin 15.6%
T263 1518-1728 Sentence denotes • Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84)
T264 1729-1839 Sentence denotes • Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone
T265 1840-1897 Sentence denotes • Statin therapy not associated with acute cardiac injury
T266 1898-2178 Sentence denotes • Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020)
T267 2179-2303 Sentence denotes • ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study
T268 2304-2368 Sentence denotes • Patients with comorbid hypertension hospitalized with COVID-19
T269 2369-2389 Sentence denotes • Age 18 to 74 years
T270 2390-2438 Sentence denotes • Primary endpoint of 28-day all-cause mortality
T271 2439-2466 Sentence denotes • N = 188 ACEi/ARB therapy
T272 2467-2530 Sentence denotes • N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension
T273 2531-2671 Sentence denotes • individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).
T274 2672-2804 Sentence denotes • Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).
T275 2805-2942 Sentence denotes • No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients
T276 2943-3053 Sentence denotes • May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)
T277 3054-3160 Sentence denotes • Statin use impact on acute myocardial injury patient outcomes • Retrospective observational cohort study
T278 3161-3194 Sentence denotes • Patients with elevated troponin
T279 3195-3230 Sentence denotes • History of CVD in 24% of patients
T280 3231-3242 Sentence denotes • N = 3069
T281 3243-3344 Sentence denotes • Objective to characterize myocardial injury and associated outcomes • 36% of patients using statins
T282 3345-3614 Sentence denotes • Doses and regimens not specified • Statin use amongst patients with acute myocardial injury was associated with improved survival HR 0.57 (95% CI 0.47–0.69) • Statin treatment may be associated with a survival benefit in patients with CVD and elevated troponin levels
T283 3615-3723 Sentence denotes • Exact beneficial mechanism(s) associated with statins in COVID-19 remain to be studied (Lala et al., 2020)